News

<< Previous Page  Displaying 9 through 11 of 11  
 
Pantec Biosolutions Receives Marketing Clearance for P.L.E.A.S.E.®
Monday, December 1, 2008
Ruggell, Liechtenstein, 01 December 2008 - Pantec Biosolutions AG, 
 
Pantec Biosolutions receives ISO 13485 certification
Wednesday, September 24, 2008
Ruggell, Liechtenstein, 24 September 2008, Pantec Biosolutions AG,
 
Pantec Biosolutions appoints new Board members
Thursday, May 15, 2008
Ruggell, Liechtenstein, 15 May 2008, Pantec Biosolutions AG, a privately-owned company developing innovative technologies for transdermal drug delivery, today announces the appointment of Burkhard Feurstein and Michael Armbruester to the Board following their election at the annual shareholders meeting held on April 24, 2008. Mr Feurstein is Director of
 
Pantec Biosolutions unveils preclinical data for novel transdermal drug delivery platform
Wednesday, April 2, 2008
Ruggell, Liechtenstein, 02 April 2008, Pantec Biosolutions AG, a privately-owned company developing innovative technologies for transdermal drug delivery, reports promising preclinical in vitro data in support of the company’s novel P.L.E.A.S.E.® intraepidermal drug delivery platform. Pantec Biosolutions has achieved further important milestones in the
 
Pantec Biosolutions presented new drug delivery platform and supporting preclinical data at Drug Delivery Partnerships 2008
Tuesday, February 5, 2008
Ruggell, Liechtenstein, 05 February 2008, Pantec Biosolutions AG, a private drug delivery company focused on innovative transdermal delivery of large molecular weight drugs, presented its novel P.L.E.A.S.E.® intraepidermal drug delivery platform at the Drug Delivery Partnerships 2008 conference in San Diego , 21-23 January 2008. At the drug delivery
 
Pantec Biosolutions successfully initiates Series A Financing Round
Thursday, December 6, 2007
Ruggell, Liechtenstein, December 06, 2007, Pantec Biosolutions AG, a private drug delivery company specialising in laser micro-poration technology for the transdermal delivery of large molecular weight drugs, has announced the successful initiation of its Series A equity investment round raising CHF 6.3 million (EURO 3.84 million, US$ 5.67 million).
 
New web animation showing how the P.L.E.A.S.E.® platform works
Wednesday, July 25, 2007
Pantec Biosolutions AG is pleased to make available to our customers, investors and partners a new web video that demonstrates very clearly how the proprietary P.L.E.A.S.E.® device creates aqueous micropores in the skin’s outer layers. It also shows the patch attachment process and the subsequent diffusion of the drug into the epidermis and dermis
 
Nomination for Swiss Medtech Award 2007
Tuesday, June 12, 2007
Pantec Biosolutions is proud to announce its nomination for the prestigious Swiss CTI Medtech Award 2007. Pantec Biosolutions has been selected together with three other finalists out of 50 candidates in the medical technology field. The Swiss Commission for Technology and Innovation (CTI) honours projects every year that have a high degree of innovation as
 
<< Previous Page 
 

More News>>

print this page